by Combat Cancer | Jun 1, 2024 | News
New HIVEC®-HEAT Phase 3 trial for bladder cancer could be a game-changer forpatients with BCG-unresponsive nonmuscle-invasive bladder cancer Combat Medical has entered into partnership with the University of Leicester, England, to run aphase 3 trial of its HIVEC®...
by Combat Cancer | May 25, 2024 | News
Bladder cancer is the seventh most commonly diagnosed solid tumour worldwide, with around 75% of cases being non-muscle-invasive. Despite its prevalence, awareness about its signs and symptoms remains alarmingly low. A recent patient survey conducted by the World...
by Combat Cancer | May 23, 2024 | News
May 23 2024 – Combat Medical has entered into partnership with the University of Leicester, England, to run a phase 3 trial of its HIVEC® treatment for BCG-unresponsive nonmuscle-invasive bladder cancer (NMIBC) as an alternative to radical cystectomy. HIVEC®-HEAT...
by Combat Cancer | May 17, 2024 | News
Bladder cancer is a significant health concern, and while it is often considered a disease that predominantly affects men, women face unique and challenging obstacles in its diagnosis and treatment. One of the most common symptoms of bladder cancer is haematuria....
by Combat Cancer | May 10, 2024 | News
Bladder cancer is a significant health concern, ranking as the 9th most common cancer worldwide. It is especially prevalent in developed countries like the UK, where lifestyle and environmental factors significantly contribute to its incidence. 1. Smoking – A...
Recent Comments